These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7514513)

  • 1. Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Mar; 40(3):373-8. PubMed ID: 7514513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic effects of growth hormone administered subcutaneously once or twice daily to growth hormone deficient adults.
    Laursen T; Jørgensen JO; Christiansen JS
    Clin Endocrinol (Oxf); 1994 Sep; 41(3):337-43. PubMed ID: 7525120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh.
    Beshyah SA; Anyaoku V; Niththyananthan R; Sharp P; Johnston DG
    Clin Endocrinol (Oxf); 1991 Nov; 35(5):409-12. PubMed ID: 1814654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of octreotide on insulin-like growth factor I and metabolic indices in growth hormone-treated growth hormone-deficient patients.
    Laursen T; Jørgensen JO; Orskov H; Møller J; Harris AG; Christiansen JS
    Acta Endocrinol (Copenh); 1993 Nov; 129(5):399-408. PubMed ID: 7506470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T; Jørgensen JO; Jakobsen G; Hansen BL; Christiansen JS
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioavailability and bioactivity of intravenous vs subcutaneous infusion of growth hormone in GH-deficient patients.
    Laursen T; Møller J; Jørgensen JO; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1996 Sep; 45(3):333-9. PubMed ID: 8949572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of growth hormone administration frequency on 24-hour growth hormone profiles and levels of other growth related parameters in girls with Turner's syndrome. Dutch Working Group on Growth Hormone.
    van Teunenbroek A; de Muinck Keizer-Schrama SM; Stijnen T; Mouton JW; Blum WF; Mercado M; Baumann G; Drop SL
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):77-84. PubMed ID: 7688672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone dose regimens in adult GH deficiency: effects on biochemical growth markers and metabolic parameters.
    Møller J; Jørgensen JO; Lauersen T; Frystyk J; Naeraa RW; Orskov H; Christiansen JS
    Clin Endocrinol (Oxf); 1993 Oct; 39(4):403-8. PubMed ID: 7507009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of GH binding activity, IGFBP-1, insulin, blood glucose and cortisol in intensive care patients.
    Ross RJ; Miell JP; Holly JM; Maheshwari H; Norman M; Abdulla AF; Buchanan CR
    Clin Endocrinol (Oxf); 1991 Oct; 35(4):361-7. PubMed ID: 1721565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The study of spontaneous GH secretion after 36-h fasting distinguishes between GH-deficient and normal adults.
    Aimaretti G; Colao A; Corneli G; Pivonello R; MacCario M; Morrison K; Pflaum CD; Strasburger CJ; Lombardi G; Ghigo E
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):771-7. PubMed ID: 10619983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability and bioactivity of three different doses of nasal growth hormone (GH) administered to GH-deficient patients: comparison with intravenous and subcutaneous administration.
    Laursen T; Grandjean B; Jørgensen JO; Christiansen JS
    Eur J Endocrinol; 1996 Sep; 135(3):309-15. PubMed ID: 8890721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites.
    Jørgensen JO; Møller N; Lauritzen T; Alberti KG; Orskov H; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jan; 70(1):207-14. PubMed ID: 2294131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term changes in serum insulin-like growth factors (IGF) and IGF binding protein 3 after different modes of intravenous growth hormone (GH) exposure in GH-deficient patients.
    Jørgensen JO; Blum WF; Møller N; Ranke MB; Christiansen JS
    J Clin Endocrinol Metab; 1991 Mar; 72(3):582-7. PubMed ID: 1705258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Administration of human recombinant insulin-like growth factor-I to patients following major gastrointestinal surgery.
    Miell JP; Taylor AM; Jones J; Buchanan CR; Rennie J; Sherwood R; Leicester R; Ross RJ
    Clin Endocrinol (Oxf); 1992 Dec; 37(6):542-51. PubMed ID: 1283730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous absorption kinetics of two highly concentrated preparations of recombinant human growth hormone.
    Laursen T; Jørgensen JO; Susgaard S; Møller J; Christiansen JS
    Ann Pharmacother; 1993 Apr; 27(4):411-5. PubMed ID: 8477114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease.
    Toogood AA; Jones J; O'Neill PA; Thorner MO; Shalet SM
    Clin Endocrinol (Oxf); 1998 May; 48(5):569-76. PubMed ID: 9666868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in serum IGF-I and IGFBP-3 concentrations during the IGF-I generation test performed prospectively in children with short stature.
    Cotterill AM; Camacho-Hübner C; Duquesnoy P; Savage MO
    Clin Endocrinol (Oxf); 1998 Jun; 48(6):719-24. PubMed ID: 9713560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
    Jørgensen JO; Møller N; Lauritzen T; Christiansen JS
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 'dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1.
    Cotterill AM; Daly F; Holly JM; Hughes SC; Camacho-Hübner C; Abdulla AF; Gale EA; Savage MO
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):567-74. PubMed ID: 8548941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome).
    Cotterill AM; Camacho-Hübner C; Holly JM; Savage MO
    Clin Endocrinol (Oxf); 1993 Jul; 39(1):119-22. PubMed ID: 7688671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.